Inovio Pharmaceuticals Inc (INO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $267.85M
Last updated: Nov 17, 2026 at 11:06 AM ET
Inovio Pharmaceuticals Inc (INO) Competitors
The companies most similar to Inovio Pharmaceuticals are Inhibikase Therapeutics (IKT), Immuneering (IMRX) and Tevogen Bio Holdings (TVGN). By market cap, Inovio Pharmaceuticals ranks 6th of the 13 companies on this page; Indaptus Therapeutics (INDP) is the largest at $422.38M.
Peer Comparison
INO's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals (INO) | $267.85M | N/A | 462.0x | 0.0% | N/A | -100.0% | 0.00% |
| Inhibikase Therapeutics Inc (IKT) | $213.21M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Immuneering Corp (IMRX) | $240.27M | N/A | N/A | 0.0% | N/A | -99.8% | 0.00% |
| Tevogen Bio Holdings Inc. (TVGN) | $406.59M | N/A | N/A | 0.0% | 2022.8% | 0.0% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| Vanda Pharmaceuticals Inc (VNDA) | $241.27M | N/A | 1.0x | -119.9% | -84.7% | 24.1% | 0.00% |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | $141.66M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | $319.27M | N/A | N/A | 0.0% | -81.5% | 0.0% | 0.00% |
| Precision BioSciences Inc (DTIL) | $288.76M | N/A | 4.4x | -85.6% | -38.3% | 37272.0% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| Indaptus Therapeutics Inc (INDP) | $422.38M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| InflaRx N.V. (IFRX) | $172.42M | N/A | N/A | 0.0% | N/A | -80.8% | 0.00% |
| Protalix Biotherapeutics Inc (PLX) | $257.17M | 12.1x | 2.9x | 24.3% | N/A | 22.8% | 0.00% |
| Peer median | $249.22M | 12.1x | 4.4x | 0.0% | -38.3% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Inovio Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Inhibikase Therapeutics Inc (IKT) | Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside... | IKT competitors |
| Immuneering Corp (IMRX) | Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its... | IMRX competitors |
| Tevogen Bio Holdings Inc. (TVGN) | Tevogen Bio Holdings Inc. is a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology... | TVGN competitors |
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| Vanda Pharmaceuticals Inc (VNDA) | Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. | VNDA competitors |
| NeOnc Technologies Holdings, Inc. Common Stock (NTHI) | NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy... | NTHI competitors |
| Kyverna Therapeutics, Inc. Common Stock (KYTX) | Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health... | KYTX competitors |
| Precision BioSciences Inc (DTIL) | Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. | DTIL competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
| Indaptus Therapeutics Inc (INDP) | Indaptus Therapeutics Inc. is a pioneering biotechnology firm focused on advancing immunotherapies that aim to transform cancer treatment paradigms. | INDP competitors |
| InflaRx N.V. (IFRX) | InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. | IFRX competitors |
| Protalix Biotherapeutics Inc (PLX) | Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its... | PLX competitors |
Frequently Asked Questions About INO
Who are Inovio Pharmaceuticals' main competitors?
The companies most similar to Inovio Pharmaceuticals include Inhibikase Therapeutics (IKT), Immuneering (IMRX), Tevogen Bio Holdings (TVGN), Innate Pharma (IPHA) and Vanda Pharmaceuticals (VNDA), listed from the closest match.
Who is Inovio Pharmaceuticals' biggest competitor?
Indaptus Therapeutics (INDP) is the largest of the similar companies at $422.38M; Inhibikase Therapeutics (IKT) is the closest match by business profile, size, sector and industry.
How does INO stock compare with its competitors?
INO's P/S is 462.0x against a peer median of 4.4x; its net margin is 0.0% against a peer median of 0.0%.
Which of Inovio Pharmaceuticals' competitors pays a higher dividend?
Inovio Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Inovio Pharmaceuticals bigger than its competitors?
No. Inovio Pharmaceuticals is 6th by market cap among the 13 companies on this page; the largest is Indaptus Therapeutics (INDP) at $422.38M.
INO pages: Overview, Earnings, Forecast, Financials, Competitors